thought call
view merck strong set posit tone balanc year
especi given substanti increas revenue/non-gaap ep guidanc notabl
guidanc rais overshadow in-lin keytruda sentiment still
tie keytruda i/o revenu may need show meaning ramp year
progress drive upsid share view quit plausibl
given growth opportun across differ indic lung penetr
china addit reimburs approv eu rcc share gain
penetr neg popul said strong keytruda
growth larg reflect street expect though see room upsid
current forecast share could face uphil battl see larger inflect
point vaccin busi meaning revenu acceler keytruda
quarterli beat given readout year wed character
higher-impact respect bd activ merck reiter prefer smaller
bolt-on acquisit view make sens given compani
remain strong commerci positionhowev manag note
valuat attract get sens merck rush
deal nearer-term overal still like merck stori root aggress
keytruda growth across i/o see littl threat keytruda domin posit
space room moder upsid strong commerci execut
pipelin advanc maintain overweight rate pt
near-term catalyst mani high-impact remaind year
profound pdufa june
model updat made model adjust reflect perform
manag commentari call chang ep estim increas
revenu detail see figur
quarterli annual ep usd
barclay research consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
overweight believ merck like
continu take share lung back
posit data addit kn-
view perhap first-
line lung market share grab us
support ow rate
faster uptak keytruda nsclc i/o
combin data acceler develop
preserv market share de-risk pipelin
posit data could put upward bia
consensu estim re-rat stock
continu weak core brand like remicad
januvia coupl faster share declin
keytruda pipelin setback could depress
revenu estim forward multipl
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
million except per share itemspriorcurrentchg chg incom net item net ep ep ep ep outstand outstand analysispriorcurrentchg chg bp gross tax growthpriorcurrentchg chg million except per share itemspriorcurrentchg chg incom net item net ep ep ep ep outstand outstand analysispriorcurrentchg chg bp gross tax growthpriorcurrentchg chg barclay merck co
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
price sourc refinitiv last avail close price relev trade market unless anoth time sourc indic
